- Home
- SKYW vs DMAC Comparison
SKYW vs DMAC Comparison
Compare SKYW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYW
- DMAC
- Stock Information
- Founded
- SKYW 1972
- DMAC 2000
- Country
- SKYW United States
- DMAC United States
- Employees
- SKYW N/A
- DMAC N/A
- Industry
- SKYW Air Freight/Delivery Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SKYW Consumer Discretionary
- DMAC Health Care
- Exchange
- SKYW Nasdaq
- DMAC Nasdaq
- Market Cap
- SKYW 4.1B
- DMAC 178.0M
- IPO Year
- SKYW N/A
- DMAC N/A
- Fundamental
- Price
- SKYW $112.54
- DMAC $3.63
- Analyst Decision
- SKYW Strong Buy
- DMAC Strong Buy
- Analyst Count
- SKYW 3
- DMAC 2
- Target Price
- SKYW $120.67
- DMAC $8.00
- AVG Volume (30 Days)
- SKYW 297.0K
- DMAC 325.9K
- Earning Date
- SKYW 07-24-2025
- DMAC 08-06-2025
- Dividend Yield
- SKYW N/A
- DMAC N/A
- EPS Growth
- SKYW 219.12
- DMAC N/A
- EPS
- SKYW 8.74
- DMAC N/A
- Revenue
- SKYW $3,672,761,000.00
- DMAC N/A
- Revenue This Year
- SKYW $12.13
- DMAC N/A
- Revenue Next Year
- SKYW $5.21
- DMAC N/A
- P/E Ratio
- SKYW $12.81
- DMAC N/A
- Revenue Growth
- SKYW 20.53
- DMAC N/A
- 52 Week Low
- SKYW $64.61
- DMAC $2.98
- 52 Week High
- SKYW $135.57
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SKYW 69.11
- DMAC 44.55
- Support Level
- SKYW $105.97
- DMAC $3.48
- Resistance Level
- SKYW $115.40
- DMAC $3.88
- Average True Range (ATR)
- SKYW 3.04
- DMAC 0.26
- MACD
- SKYW 1.06
- DMAC 0.00
- Stochastic Oscillator
- SKYW 84.86
- DMAC 30.10
About SKYW SkyWest Inc.
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.